Market and Product Forecasts: HER2-Negative/Hormone Receptor-Positive Breast Cancer -

2012-08-19 11:39:42 - Patent expiries and novel drugs shape the market in the next decade

The treatment of HER2-negative/hormone receptor-positive breast cancer consists largely of genericized cytotoxic and antihormonal therapies. Avastin (bevacizumab) is currently the only targeted therapy used in this patient population. Patent expiries and the uptake of novel targeted drugs will help shape the market in the next decade, but little change is anticipated in the overall market value.

Scope
* Analysis of HER2-negative/hormone

receptor-positive breast cancer drugs in the seven major markets
* Patient based sales forecast for drugs in the HER2-negative/hormone receptor-positive breast cancer market from 2011 to 2020
* In depth analysis of the factors influencing the HER2-negative/hormone receptor-positive breast cancer drug sales in the seven major markets
* Molecule dynamics and assessment of the key HER2-negative/hormone receptor-positive breast cancer drugs in the seven major markets


Full Report Details at
- www.fastmr.com/prod/449040_market_and_product_forecasts_her2nega ..


Highlights

The HER2-/HR+ breast cancer market will experience a modest decrease in sales over the forecast period. The value of the market is forecast to decrease from nearly $5.0bn in 2011 to about $4.7bn in 2020 in the seven major markets (the US, Japan, France, Germany, Italy, Spain, and the UK), representing a CAGR of -0.69%.

The patent expiry of Xeloda will have a big impact on the value of the market. Xeloda (capecitabine; Genentech/Roche/Chugai) is forecast to be the highest-selling chemotherapy in the HER2-negative/hormone receptor-positive breast cancer market in 2012, with sales of over $650m in the seven major markets.

Novel targeted therapies will gain a small share of the market. Three novel targeted therapies - Novartis's Afinitor (everolimus), Bayer Schering/Onyx's Nexavar (sorafenib), and Eli Lilly's ramucirumab - are expected to enter the HER2-negative/hormone receptor-positive breast cancer market within the forecast period.

Reasons to Get this Report
* Quantify the performance of each of HER2-/HR+ breast cancer drug in the seven major markets by molecule and regimen sales.
* Gain insight into the key trends in individual HER2-/HR+ breast cancer markets across the seven major markets.
* The report is accompanied by a PowerPoint presentation and Excel deliverable showing full HER2-/HR+ breast cancer forecasts for the US, Japan and 5EU.

Partial Table of Contents:

OVERVIEW

* Catalyst
* Summary

EXECUTIVE SUMMARY

* Strategic scoping and focus
* Datamonitor key findings
* Related reports

MARKET DEFINITION

* Market definition for HER2-negative/hormone receptor-positive breast cancer
* Forecast methodology and assumptions

* Methodology flow
* New product launches

* Additional forecast methodology

MARKET OVERVIEW AND CONTEXT

* Cancer therapies included in this report
* Current and future market dynamics overview

* The value of the HER2-negative/hormone receptor-positive breast cancer market will change little over 2011-20
* Market value is accumulated in the treatment of early-stage disease and distant relapse
* Adjuvant hormonal therapy sales contribute the maximum value to the market
* The commercial value of targeted therapies will increase in the forecast period but sales of cytotoxics will decline
* The value of the US market will decline slightly over 2011-20
* The Japanese market will grow slightly over 2011-20
* Sales in the five major EU markets will experience a small decline

PRODUCT FORECASTS

* Molecule dynamics

* Anastrozole will be the highest grossing molecule in 2012

* Avastin (bevacizumab; Genentech/Roche/Chugai)
* Ramucirumab (Eli Lilly)
* Xeloda (capecitabine; Genentech/Roche/Chugai)
* Anastrozole (generic)
* Afinitor (everolimus; Novartis)
* Nexavar (sorafenib; Bayer Schering/Onyx)

BIBLIOGRAPHY

* Websites
* Datamonitor reports

APPENDIX

* Forecast methodology

* Volume and value forecast methodology
* Price and compliance assumptions

* Report methodology

TABLES

* Table: Summary of therapeutic classes in HER2-negative/hormone receptor-positive breast cancer by Anatomical Therapeutic Chemical code, 2012
* Table: Estimated launch dates for key late-stage pipeline and marketed products forecast to enter the HER2-negative/hormone receptor-positive breast cancer, 2011-20
* Table: Drugs included in the HER2-negative/hormone receptor-positive breast cancer market and product forecasts, 2011-20
* Table: Forecast number of HER2-negative/hormone receptor-positive breast cancer patients in the seven major markets, by stage of disease, 2012
* Table: Forecast molecule sales for HER2-negative/hormone receptor-positive breast cancer in the seven major markets ($m), 2011-20
* Table: Forecast chemotherapy regimen sales for HER2-negative/hormone receptor-positive breast cancer in the seven major markets ($m), 2011-20
* Table: Forecast hormonal therapy regimen sales for HER2-negative/hormone receptor-positive breast cancer in the seven major markets ($m), 2011-20
* Table: Forecast molecule sales in the US for HER2-negative/hormone receptor-positive breast cancer ($m), 2011-20
* Table: Forecast molecule sales in Japan for HER2- negative/hormone receptor-positive breast cancer ($m), 2011-20
* Table: Forecast molecule sales in the five major EU markets for HER2-negative/hormone receptor-positive breast cancer ($m), 2011-20
* Table: Key HER2-negative/hormone receptor-positive breast cancer molecule sales in the seven major markets, 2011 and 2020
* Table: Avastin sales, by country ($m), 2011-20
*

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=449040&dt=t

About Datamonitor

The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment. View more research from Datamonitor at www.fastmr.com/catalog/publishers.aspx?pubid=1002

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.